Retinal Vein Occlusion – Ranibizumab for CRVO

Who is the sponsor?
California Retina Research Foundation

Who are the patients?
Male or female 18 Years and older with center-involved macular edema secondary to CRVO.

How long are the eligible patients enrollment?
All subjects are monitored for two years.

What is this study investigating?
This study will determine the efficacy, safety, and tolerability of intravitreal injections in participants with macular edema secondary to Central Retinal Vein Occlusion. Either a 0.5 mg dose or a 2.0 mg dose of ranibizumab will be injected on an as needed basis, after an initial three injections up to one year. This study will determine if ranibizumab is effective in the treatment of macular edema and if the 2.0 mg dose of ranibizumab is more effective than the 0.5mg dose.